Pleural Effusion

Detailed Overview

Normally, 10-20 mL of fluid lubricates the pleural space, continuously produced by the parietal pleura and absorbed by lymphatic stomata. An effusion develops when fluid production exceeds absorption. Effusions are broadly classified into transudates (resulting from systemic imbalances in hydrostatic or oncotic pressure) and exudates (resulting from local pleural inflammation or altered capillary permeability). Identifying the underlying cause via thoracentesis and fluid analysis using Light's criteria is critical for guiding therapy.

Epidemiology & Demographics

Affects approximately 1.5 million people annually in the United States. Congestive heart failure is the most common cause of transudative effusions, while pneumonia and malignancy are the leading causes of exudative effusions.

Etiological Mechanism

Transudative causes: Heart failure (most common), cirrhosis, nephrotic syndrome. Exudative causes: Parapneumonic (bacterial pneumonia), malignancy (lung, breast, lymphoma), pulmonary embolism, tuberculosis, connective tissue diseases (rheumatoid arthritis, lupus).

Primary Causes

Elevated pulmonary capillary hydrostatic pressure, decreased plasma oncotic pressure, increased pleural capillary permeability, lymphatic obstruction, or movement of fluid from the peritoneal cavity (hepatic hydrothorax).

• Heart Failure: High left-sided filling pressures back up into the pulmonary circulation, driving fluid into the pleural space.
• Pneumonia: Causes local inflammation (parapneumonic effusion) which can progress to an infected space (empyema).
• Malignancy: Tumor involvement of the pleura blocks lymphatic drainage or directly secretes fluid.
• Cirrhosis: Hypoalbuminemia and fluid shifts through diaphragmatic defects cause transudative effusions.

The pleural fluid turnover is governed by Starling forces. In a healthy state, the hydrostatic pressure pushing fluid out of parietal capillaries is balanced by lymphatic drainage. Transudates form when systemic hydrostatic pressure is profoundly elevated (e.g., LVEDP > 15 mmHg in CHF) or oncotic pressure is depressed (e.g., Albumin < 2.5 g/dL). Exudates occur when local pathology (infection, tumor, infarction) triggers the release of inflammatory cytokines (like VEGF and histamine). This causes endothelial gap widening, allowing protein-rich fluid and cells to leak into the pleural space. Large effusions mechanically compress the underlying lung parenchyma (compressive atelectasis), reducing compliance and impairing gas exchange, leading to dyspnea.

Characteristic Clinical Presentation

• Dyspnea: Progressive shortness of breath, particularly worsening when lying flat (orthopnea) if the effusion is large.
• Pleuritic Chest Pain: Sharp, stabbing pain localized to the chest wall, worsening with deep inspiration or coughing (typically implies an exudate).
• Dry Cough: Non-productive cough caused by inflammation of the pleura or lung compression.

Physical Examination Signs

• Dullness to percussion over the affected hemithorax.
• Decreased or absent breath sounds over the effusion.
• Decreased tactile fremitus (differentiates effusion from consolidation, where fremitus is increased).
• Asymmetric chest expansion, lagging on the affected side.

• Empyema: Infection of the pleural fluid creating a pocket of pus, highly resistant to systemic antibiotics.
• Trapped Lung: Formation of a fibrous peel over the visceral pleura from chronic inflammation, preventing lung expansion even after fluid removal.
• Tension Hydrothorax: Massive effusion causing mediastinal shift and hemodynamic compromise.

Diagnostic Criteria & Guidelines

Diagnosis requires imaging confirmation of fluid, followed by thoracentesis. Light's Criteria classifies it as an EXUDATE if at least one of the following is present: Pleural fluid protein / Serum protein > 0.5; Pleural fluid LDH / Serum LDH > 0.6; Pleural fluid LDH > 2/3 the upper limit of normal for serum LDH.

Differential Diagnosis

• Congestive Heart Failure
• Pneumonia
• Malignancy (Lung cancer, Mesothelioma)
• Pulmonary Embolism

Laboratory Tests & Biomarkers

• Pleural Fluid pH: < 7.20 indicates a complicated parapneumonic effusion or empyema, necessitating chest tube drainage.
• Pleural Fluid Glucose: < 60 mg/dL seen in complicated parapneumonic effusions, malignancy, rheumatoid arthritis, and tuberculosis.
• Pleural Fluid NT-proBNP: > 1500 pg/mL strongly supports heart failure as the cause of a transudate.
• Pleural Fluid Cytology: Positive for malignant cells in neoplastic effusions.

Imaging Modalities & Findings

• Chest X-ray (PA and Lateral): Blunting of the costophrenic angle; >175 mL fluid needed for PA blunting, >50 mL for lateral blunting. Meniscus sign present.
• Thoracic Ultrasound: Highly sensitive; identifies anechoic (black) fluid collections, septations, and guides safe thoracentesis.
• CT Chest with contrast: Differentiates pleural fluid from lung consolidation, detects loculations, pleural thickening, and underlying parenchymal masses.

• Uncomplicated Parapneumonic
  Free-flowing, sterile exudate associated with pneumonia; resolves with antibiotics.
• Complicated Parapneumonic
  Fluid infected by bacteria (pH < 7.20, Glucose < 60); requires drainage.
• Empyema
  Frank pus in the pleural space; requires urgent drainage and possibly decortication.

Second-Line & Adjunctive Therapy

For Complicated Parapneumonic/Empyema: Prompt placement of a tube thoracostomy (chest tube, e.g., 14F pigtail) for continuous drainage. For Malignant effusions: Indwelling pleural catheter (PleurX) or chemical pleurodesis using Talc (e.g., 4g sterile talc slurry) to obliterate the pleural space.

Surgical & Procedural Management

Video-Assisted Thoracoscopic Surgery (VATS) with decortication is indicated for loculated empyemas or trapped lung that fail conservative chest tube drainage or intrapleural fibrinolytics (tPA + DNase).

Recommended Lifestyle Changes

• Sodium restriction (<2g/day) if the etiology is heart failure or cirrhosis.
• Smoking cessation to reduce the risk of pulmonary infections and malignancies.
• Upright posture or sleeping with the head of the bed elevated to ease breathing.

Patient Counseling & Advice

Explain that the procedure to drain the fluid (thoracentesis) provides quick relief but does not cure the problem; the fluid may return until the root cause (like heart failure or infection) is effectively treated.

Follow-Up & Monitoring Schedule

Repeat CXR or bedside ultrasound in 24-48 hours post-drainage to assess for fluid re-accumulation or pneumothorax. Continued monitoring of the underlying systemic disease.

Preventive Strategies

Vaccination against Pneumococcus and Influenza to prevent pneumonia. Optimization of medical therapy for heart failure.

Highly dependent on the etiology. Transudates from CHF have a fair prognosis if managed. Malignant effusions generally portend a poor prognosis, with a median survival of 3-12 months. Empyema carries a 15% mortality rate in the elderly.